Roots Analysis

FEBRUARY 26, 2024

Given the robust pipeline of biologics, which include monoclonal antibodies, vaccines and other protein-based therapeutic products, subcutaneous medications are being investigated for various clinical candidates across different phases of development.

Drug Delivery Systems 52

Drug Delivery Systems Drug Delivery Drugs Contract Manufacturing 52

Roots Analysis

MARCH 21, 2022

However, several drug delivery devices that enable patients to self-administer their respective medications are now available. Subcutaneous drug delivery systems – the helping hand for patients. The emergence of safer and patient-friendly devices is acting as a strong enabler for subcutaneous delivery of therapeutics.

Drug Delivery Systems 52

Drug Delivery Systems Drug Delivery Antibody Drugs 52

XTalks

OCTOBER 1, 2024

mRNA therapies work by instructing cells to produce specific proteins that can enhance the body’s natural defenses or correct deficiencies. ETH47, Ethris’ investigational mRNA therapeutic, is designed to address this vulnerability by encoding for interferon lambda, a crucial protein in the immune response. “By

Development 52

Development Drugs Immune Response Protein 52

Roots Analysis

OCTOBER 22, 2023

Coding RNAs include messenger RNA (mRNA) and short interfering RNA (siRNA), which encode proteins and silence gene expression, respectively. ASOs are short single-stranded nucleotides that bind to specific messenger RNAs and prevent the production of a particular protein.

RNA 40

RNA Protein Genetics Gene Expression 40

The Pharma Data

JANUARY 16, 2021

Etta Biotech”), to set up a high titer transient protein expression platform for high quality protein production using JS Bio’s transient transfection media. JS Bio becomes the exclusive cell culture supplier for Etta Biotech’s transient transfection high titer protein expression platform. JS Bio’s parent company.

Protein 52

Protein Production Antibody In-Vitro 52

pharmaphorum

SEPTEMBER 22, 2021

Its lead project is a T-cell receptor (TCR)-like antibody against an HLA molecule associated with intracellular protein NKG2A, an immune checkpoint. Abexxa will form part of its broad push into immuno-oncology, focused on cancer vaccines, oncolytic viruses and T-cell engagers, amongst other treatment strategies.

Antibody 92

Antibody Drug Delivery Vaccination Vaccine 92

Roots Analysis

MARCH 13, 2022

In the last decade alone, the annual number of approvals of biopharmaceuticals (including monoclonal antibodies, recombinant proteins, vaccines and gene therapies), by the US FDA, have steadily risen. Over the years, the rising popularity of biologics has led to a paradigm shift in the healthcare industry. Our Social Media Platform.

Manufacturing 52

Manufacturing Drug Delivery Marketing Drug Delivery Systems 52

Roots Analysis

FEBRUARY 13, 2023

Messenger ribonucleic acid (mRNA) is a single-stranded molecule, which carries coding sequence and plays a prominent role in protein synthesis. It transfers genetic information form to DNA to ribosomes, a specialized structure, or organelle, which decodes genetic information into a protein.

Manufacturing 52

Manufacturing Drug Delivery Systems Genetic Engineering RNA 52

Roots Analysis

MARCH 9, 2022

In the last decade alone, the annual number of approvals of biopharmaceuticals (including monoclonal antibodies, recombinant proteins, vaccines, and gene therapies), by the US FDA, have steadily risen. Over the years, the rising popularity of biologics has led to a paradigm shift in the healthcare industry.

Manufacturing 52

Manufacturing Marketing Contract Manufacturing Protein 52

The Pharma Data

JUNE 7, 2023

Acuitas’ LNP technology will support Bayer’s in vivo gene editing and protein replacement programs by specifically delivering RNA payloads to the desired target organ, the liver. LNPs are spheric drug delivery bodies which can be equipped with therapeutic payloads for intracellular delivery.

Gene Therapy 40

Gene Therapy Gene Gene Editing In-Vivo 40

XTalks

OCTOBER 11, 2024

This study adds significant findings to Arexvy’s profile as the first RSV vaccine to show protection over such an extended period. Approved by the US Food and Drug Administration (FDA) in May 2023, Arexvy is designed to prevent lower respiratory tract disease (LRTD) caused by RSV in older adults. Efficacy over the entire study was 62.9

Vaccination 103

Vaccination Vaccine Immune Response Trials 103

Roots Analysis

MAY 21, 2024

LNPs comprise of a lipid bilayer that surrounds a hydrophobic core, which can be loaded with therapeutic agents ( such as drugs, genetic material and proteins ). The average size of LNPs typically ranges from 40 to 1,000 nanometers, which allows efficient cellular uptake and intracellular delivery.

Drug Delivery 40

Drug Delivery Drugs Gene Therapy Bioavailability 40

The Pharma Data

JANUARY 15, 2021

Food and Drug Administration (FDA) approval of Darzalex Faspro ® (daratumumab and hyaluronidase-fihj), a subcutaneous formulation of daratumumab, in combination with bortezomib, cyclophosphamide and dexamethasone (D-VCd) for the treatment of adult patients with newly diagnosed light chain (AL) amyloidosis.[1] Learn more at www.janssen.com.

FDA Approval 52

FDA Approval Production Research Development 52

Roots Analysis

JANUARY 27, 2025

In order to help circumvent these disadvantages, several drug delivery devices, which enable patients to self-administer drugs through subcutaneous route are now being developed. Further, majority of the approved subcutaneous biologics are proteins.

Marketing 40

Marketing Drug Delivery Development Protein 40